176 related articles for article (PubMed ID: 38618931)
1. Experimental and new investigational drugs for the treatment of uterine fibroids.
Evangelisti G; Ferrero S; Perrone U; Gustavino C; Volpi E; Izzotti A; Barra F
Expert Opin Investig Drugs; 2024 Apr; ():1-12. PubMed ID: 38618931
[TBL] [Abstract][Full Text] [Related]
2. Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids.
Evangelisti G; Barra F; Perrone U; Di Donato N; Bogliolo S; Ceccaroni M; Ferrero S
Expert Opin Drug Metab Toxicol; 2022; 18(7-8):441-457. PubMed ID: 35968602
[TBL] [Abstract][Full Text] [Related]
3. Preoperative medical therapy before surgery for uterine fibroids.
Lethaby A; Puscasiu L; Vollenhoven B
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD000547. PubMed ID: 29139105
[TBL] [Abstract][Full Text] [Related]
4. Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis.
Arjona Ferreira JC; Migoya E
F S Rep; 2023 Jun; 4(2 Suppl):73-82. PubMed ID: 37223761
[TBL] [Abstract][Full Text] [Related]
5. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
6. Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids.
Syed YY
Drugs; 2022 Oct; 82(15):1549-1556. PubMed ID: 36331779
[TBL] [Abstract][Full Text] [Related]
7. Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids.
Al-Hendy A; Bradley L; Owens CD; Wang H; Barnhart KT; Feinberg E; Schlaff WD; Puscheck EE; Wang A; Gillispie V; Hurtado S; Muneyyirci-Delale O; Archer DF; Carr BR; Simon JA; Stewart EA
Am J Obstet Gynecol; 2021 Jan; 224(1):72.e1-72.e50. PubMed ID: 32702363
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic drugs in the treatment of symptomatic uterine fibroids.
Hoellen F; Griesinger G; Bohlmann MK
Expert Opin Pharmacother; 2013 Oct; 14(15):2079-85. PubMed ID: 23914973
[TBL] [Abstract][Full Text] [Related]
9. Considerations on implementation of the newest treatment for symptomatic uterine fibroids: Oral GnRH antagonists.
de Lange ME; Semmler A; Clark TJ; Mol BWJ; Bet PM; Huirne JAF; Hehenkamp WJK
Br J Clin Pharmacol; 2024 Feb; 90(2):392-405. PubMed ID: 37653680
[TBL] [Abstract][Full Text] [Related]
10. Measurement of changes in uterine and fibroid volume during treatment of heavy menstrual bleeding (HMB).
Yin K; Whitaker L; Hojo E; McLenachan S; Walker J; McKillop G; Stubbs C; Priest L; Cruz M; Roberts N; Critchley H
Hum Reprod Open; 2023; 2023(3):hoad021. PubMed ID: 37304815
[TBL] [Abstract][Full Text] [Related]
11. Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials.
Stewart EA; Lukes AS; Venturella R; Li Y; Hunsche E; Wagman RB; Al-Hendy A
Am J Obstet Gynecol; 2023 Mar; 228(3):320.e1-320.e11. PubMed ID: 36370871
[TBL] [Abstract][Full Text] [Related]
12. The potential of selective progesterone receptor modulators for the treatment of uterine fibroids.
Bestel E; Donnez J
Expert Rev Endocrinol Metab; 2014 Jan; 9(1):79-92. PubMed ID: 30743741
[TBL] [Abstract][Full Text] [Related]
13. The management of uterine leiomyomas.
Vilos GA; Allaire C; Laberge PY; Leyland N;
J Obstet Gynaecol Can; 2015 Feb; 37(2):157-178. PubMed ID: 25767949
[TBL] [Abstract][Full Text] [Related]
14. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
Szamatowicz M; Kotarski J
Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
[TBL] [Abstract][Full Text] [Related]
15. Fibroids and unexplained infertility treatment with epigallocatechin gallate: a natural compound in green tea (FRIEND) - protocol for a randomised placebo-controlled US multicentre clinical trial of EGCG to improve fertility in women with uterine fibroids.
Al-Hendy A; Segars JH; Taylor HS; González F; Siblini H; Zamah M; Alkelani H; Singh B; Flores VA; Christman GM; Johnson JJ; Huang H; Zhang H
BMJ Open; 2024 Jan; 14(1):e078989. PubMed ID: 38216200
[TBL] [Abstract][Full Text] [Related]
16. Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study.
Stewart EA; Al-Hendy A; Lukes AS; Madueke-Laveaux OS; Zhu E; Proehl S; Schulmann T; Marsh EE
Am J Obstet Gynecol; 2024 Feb; 230(2):237.e1-237.e11. PubMed ID: 37863160
[TBL] [Abstract][Full Text] [Related]
17. Place of ulipristal acetate in the management of uterine fibroids: Preoperative treatment or sequential treatment?
Pourcelot AG; Capmas P; Fernandez H
J Gynecol Obstet Hum Reprod; 2017 Mar; 46(3):249-254. PubMed ID: 28403922
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids.
Ferrero S; Vellone VG; Barra F
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):107-116. PubMed ID: 29250979
[TBL] [Abstract][Full Text] [Related]
19. Use of oral GnRH antagonists combined therapy in the management of symptomatic uterine fibroids.
Di Spiezio Sardo A; Ciccarone F; Muzii L; Scambia G; Vignali M
Facts Views Vis Obgyn; 2023 Mar; 15(1):29-33. PubMed ID: 37010332
[TBL] [Abstract][Full Text] [Related]
20. Current medical treatment of uterine fibroids.
Sohn GS; Cho S; Kim YM; Cho CH; Kim MR; Lee SR;
Obstet Gynecol Sci; 2018 Mar; 61(2):192-201. PubMed ID: 29564309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
